Sanfa Fe, Argentina – Q2 2025 – Single Strand Biotech (SSBio), a fast-growing biotech start-up focused on the development of next-generation immunomodulatory drug candidates, is proud to announce that it has officially joined the investment portfolio of CITES, the corporate venture capital fund of Grupo Sancor Seguros (Argentina).
This milestone marks the closing of our pre-seed financing round, which will support the advancement of our proprietary synthetic oligonucleotide platform and the development of innovative therapies for chronic inflammatory diseases, including Inflammatory Bowel Disease (IBD).
“Having CITES as SSBio’s first investor is a transformative milestone”, said Alejandro Montaner, CEO of Single Strand Biotech. “Their support allows us to accelerate R&D and swiftly move into preclinical safety studies, the first step toward bringing breakthrough therapies to patients”.